Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,843
archived clinical trials in
Prostate Cancer

Phase I Targeting Dominant Intraprostatic Lesion Using MR Spectroscopy and HDR Brachytherapy
Phase I Study of Targeting Dominant Intraprostatic Lesion Using Functional MR Spectroscopy and High Dose Rate Brachytherapy
Status: Archived
Unversity of California, San Francisco
1340
mi
from
San Francisco, CA
Phase I Targeting Dominant Intraprostatic Lesion Using MR Spectroscopy and HDR Brachytherapy
Phase I Study of Targeting Dominant Intraprostatic Lesion Using Functional MR Spectroscopy and High Dose Rate Brachytherapy
Status: Archived
Updated: 1/1/1970
Unversity of California, San Francisco
1340
mi
from
San Francisco, CA
Biomarker Study of Neoadjuvant Vitamin E in Patients With Locally Treatable Prostate Cancer
A Phase III Biomarker Study of Neoadjuvant Vitamin E in Patients With Locally Treatable Prostate Cancer Prior to Prostatectomy or Brachytherapy
Status: Archived
Universtiy of New Mexico - Cancer Center
522
mi
from
Albuquerque, NM
Biomarker Study of Neoadjuvant Vitamin E in Patients With Locally Treatable Prostate Cancer
A Phase III Biomarker Study of Neoadjuvant Vitamin E in Patients With Locally Treatable Prostate Cancer Prior to Prostatectomy or Brachytherapy
Status: Archived
Updated: 1/1/1970
Universtiy of New Mexico - Cancer Center
522
mi
from
Albuquerque, NM
Neoadjuvant Weekly Ixabepilone for High Risk, Clinically Localized Prostate Cancer
BrUOG-PROS-221 Neoadjuvant Weekly Ixabepilone for High Risk, Clinically Localized Prostate Cancer: A Phase II Study
Status: Archived
The Miriam Hospital's Weight Control and Diabetes Research Center
1424
mi
from
Providence, RI
Neoadjuvant Weekly Ixabepilone for High Risk, Clinically Localized Prostate Cancer
BrUOG-PROS-221 Neoadjuvant Weekly Ixabepilone for High Risk, Clinically Localized Prostate Cancer: A Phase II Study
Status: Archived
Updated: 1/1/1970
The Miriam Hospital's Weight Control and Diabetes Research Center
1424
mi
from
Providence, RI
Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer
A Randomised, Parallel Arm, Open-label Trial Comparing Degarelix With Goserelin Plus Anti-androgen Flare Protection (Bicalutamide), in Terms of Prostate Size Reduction in Prostate Cancer Patients of Intermediate-to-high Risk, Who Require Neoadjuvant Hormone Therapy Prior to Radiotherapy (Curative Intent)
Status: Archived
Alabama Research Center
685
mi
from
Birmingham, AL
Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer
A Randomised, Parallel Arm, Open-label Trial Comparing Degarelix With Goserelin Plus Anti-androgen Flare Protection (Bicalutamide), in Terms of Prostate Size Reduction in Prostate Cancer Patients of Intermediate-to-high Risk, Who Require Neoadjuvant Hormone Therapy Prior to Radiotherapy (Curative Intent)
Status: Archived
Updated: 1/1/1970
Alabama Research Center
685
mi
from
Birmingham, AL
Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer
A Randomised, Parallel Arm, Open-label Trial Comparing Degarelix With Goserelin Plus Anti-androgen Flare Protection (Bicalutamide), in Terms of Prostate Size Reduction in Prostate Cancer Patients of Intermediate-to-high Risk, Who Require Neoadjuvant Hormone Therapy Prior to Radiotherapy (Curative Intent)
Status: Archived
Urology Centers of Alabama
685
mi
from
Homewood, AL
Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer
A Randomised, Parallel Arm, Open-label Trial Comparing Degarelix With Goserelin Plus Anti-androgen Flare Protection (Bicalutamide), in Terms of Prostate Size Reduction in Prostate Cancer Patients of Intermediate-to-high Risk, Who Require Neoadjuvant Hormone Therapy Prior to Radiotherapy (Curative Intent)
Status: Archived
Updated: 1/1/1970
Urology Centers of Alabama
685
mi
from
Homewood, AL
Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer
A Randomised, Parallel Arm, Open-label Trial Comparing Degarelix With Goserelin Plus Anti-androgen Flare Protection (Bicalutamide), in Terms of Prostate Size Reduction in Prostate Cancer Patients of Intermediate-to-high Risk, Who Require Neoadjuvant Hormone Therapy Prior to Radiotherapy (Curative Intent)
Status: Archived
Alaska Urological Association
2732
mi
from
Anchorage, AK
Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer
A Randomised, Parallel Arm, Open-label Trial Comparing Degarelix With Goserelin Plus Anti-androgen Flare Protection (Bicalutamide), in Terms of Prostate Size Reduction in Prostate Cancer Patients of Intermediate-to-high Risk, Who Require Neoadjuvant Hormone Therapy Prior to Radiotherapy (Curative Intent)
Status: Archived
Updated: 1/1/1970
Alaska Urological Association
2732
mi
from
Anchorage, AK
Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer
A Randomised, Parallel Arm, Open-label Trial Comparing Degarelix With Goserelin Plus Anti-androgen Flare Protection (Bicalutamide), in Terms of Prostate Size Reduction in Prostate Cancer Patients of Intermediate-to-high Risk, Who Require Neoadjuvant Hormone Therapy Prior to Radiotherapy (Curative Intent)
Status: Archived
Arizona Urologic Specialists
830
mi
from
Tuscon, AZ
Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer
A Randomised, Parallel Arm, Open-label Trial Comparing Degarelix With Goserelin Plus Anti-androgen Flare Protection (Bicalutamide), in Terms of Prostate Size Reduction in Prostate Cancer Patients of Intermediate-to-high Risk, Who Require Neoadjuvant Hormone Therapy Prior to Radiotherapy (Curative Intent)
Status: Archived
Updated: 1/1/1970
Arizona Urologic Specialists
830
mi
from
Tuscon, AZ
Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer
A Randomised, Parallel Arm, Open-label Trial Comparing Degarelix With Goserelin Plus Anti-androgen Flare Protection (Bicalutamide), in Terms of Prostate Size Reduction in Prostate Cancer Patients of Intermediate-to-high Risk, Who Require Neoadjuvant Hormone Therapy Prior to Radiotherapy (Curative Intent)
Status: Archived
Orange County Urology
1150
mi
from
Lagua Hills, CA
Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer
A Randomised, Parallel Arm, Open-label Trial Comparing Degarelix With Goserelin Plus Anti-androgen Flare Protection (Bicalutamide), in Terms of Prostate Size Reduction in Prostate Cancer Patients of Intermediate-to-high Risk, Who Require Neoadjuvant Hormone Therapy Prior to Radiotherapy (Curative Intent)
Status: Archived
Updated: 1/1/1970
Orange County Urology
1150
mi
from
Lagua Hills, CA
Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer
A Randomised, Parallel Arm, Open-label Trial Comparing Degarelix With Goserelin Plus Anti-androgen Flare Protection (Bicalutamide), in Terms of Prostate Size Reduction in Prostate Cancer Patients of Intermediate-to-high Risk, Who Require Neoadjuvant Hormone Therapy Prior to Radiotherapy (Curative Intent)
Status: Archived
Tri-Valley Urology Medical Group
1120
mi
from
Murrieta, CA
Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer
A Randomised, Parallel Arm, Open-label Trial Comparing Degarelix With Goserelin Plus Anti-androgen Flare Protection (Bicalutamide), in Terms of Prostate Size Reduction in Prostate Cancer Patients of Intermediate-to-high Risk, Who Require Neoadjuvant Hormone Therapy Prior to Radiotherapy (Curative Intent)
Status: Archived
Updated: 1/1/1970
Tri-Valley Urology Medical Group
1120
mi
from
Murrieta, CA
Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer
A Randomised, Parallel Arm, Open-label Trial Comparing Degarelix With Goserelin Plus Anti-androgen Flare Protection (Bicalutamide), in Terms of Prostate Size Reduction in Prostate Cancer Patients of Intermediate-to-high Risk, Who Require Neoadjuvant Hormone Therapy Prior to Radiotherapy (Curative Intent)
Status: Archived
Connecticut Clinical Research Center, LLC
1335
mi
from
Middlebury, CT
Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer
A Randomised, Parallel Arm, Open-label Trial Comparing Degarelix With Goserelin Plus Anti-androgen Flare Protection (Bicalutamide), in Terms of Prostate Size Reduction in Prostate Cancer Patients of Intermediate-to-high Risk, Who Require Neoadjuvant Hormone Therapy Prior to Radiotherapy (Curative Intent)
Status: Archived
Updated: 1/1/1970
Connecticut Clinical Research Center, LLC
1335
mi
from
Middlebury, CT
Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer
A Randomised, Parallel Arm, Open-label Trial Comparing Degarelix With Goserelin Plus Anti-androgen Flare Protection (Bicalutamide), in Terms of Prostate Size Reduction in Prostate Cancer Patients of Intermediate-to-high Risk, Who Require Neoadjuvant Hormone Therapy Prior to Radiotherapy (Curative Intent)
Status: Archived
South Florida Medical Research
1314
mi
from
Miami, FL
Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer
A Randomised, Parallel Arm, Open-label Trial Comparing Degarelix With Goserelin Plus Anti-androgen Flare Protection (Bicalutamide), in Terms of Prostate Size Reduction in Prostate Cancer Patients of Intermediate-to-high Risk, Who Require Neoadjuvant Hormone Therapy Prior to Radiotherapy (Curative Intent)
Status: Archived
Updated: 1/1/1970
South Florida Medical Research
1314
mi
from
Miami, FL
Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer
A Randomised, Parallel Arm, Open-label Trial Comparing Degarelix With Goserelin Plus Anti-androgen Flare Protection (Bicalutamide), in Terms of Prostate Size Reduction in Prostate Cancer Patients of Intermediate-to-high Risk, Who Require Neoadjuvant Hormone Therapy Prior to Radiotherapy (Curative Intent)
Status: Archived
DCT -Celebration, LLC dba Discovery Clinical Trials
1140
mi
from
Celebration, FL
Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer
A Randomised, Parallel Arm, Open-label Trial Comparing Degarelix With Goserelin Plus Anti-androgen Flare Protection (Bicalutamide), in Terms of Prostate Size Reduction in Prostate Cancer Patients of Intermediate-to-high Risk, Who Require Neoadjuvant Hormone Therapy Prior to Radiotherapy (Curative Intent)
Status: Archived
Updated: 1/1/1970
DCT -Celebration, LLC dba Discovery Clinical Trials
1140
mi
from
Celebration, FL
Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer
A Randomised, Parallel Arm, Open-label Trial Comparing Degarelix With Goserelin Plus Anti-androgen Flare Protection (Bicalutamide), in Terms of Prostate Size Reduction in Prostate Cancer Patients of Intermediate-to-high Risk, Who Require Neoadjuvant Hormone Therapy Prior to Radiotherapy (Curative Intent)
Status: Archived
Pinellas Urology Inc.
1112
mi
from
St. Petersburg, FL
Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer
A Randomised, Parallel Arm, Open-label Trial Comparing Degarelix With Goserelin Plus Anti-androgen Flare Protection (Bicalutamide), in Terms of Prostate Size Reduction in Prostate Cancer Patients of Intermediate-to-high Risk, Who Require Neoadjuvant Hormone Therapy Prior to Radiotherapy (Curative Intent)
Status: Archived
Updated: 1/1/1970
Pinellas Urology Inc.
1112
mi
from
St. Petersburg, FL
Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer
A Randomised, Parallel Arm, Open-label Trial Comparing Degarelix With Goserelin Plus Anti-androgen Flare Protection (Bicalutamide), in Terms of Prostate Size Reduction in Prostate Cancer Patients of Intermediate-to-high Risk, Who Require Neoadjuvant Hormone Therapy Prior to Radiotherapy (Curative Intent)
Status: Archived
Palm Beach Urology Associates
1277
mi
from
Wellington, FL
Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer
A Randomised, Parallel Arm, Open-label Trial Comparing Degarelix With Goserelin Plus Anti-androgen Flare Protection (Bicalutamide), in Terms of Prostate Size Reduction in Prostate Cancer Patients of Intermediate-to-high Risk, Who Require Neoadjuvant Hormone Therapy Prior to Radiotherapy (Curative Intent)
Status: Archived
Updated: 1/1/1970
Palm Beach Urology Associates
1277
mi
from
Wellington, FL
Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer
A Randomised, Parallel Arm, Open-label Trial Comparing Degarelix With Goserelin Plus Anti-androgen Flare Protection (Bicalutamide), in Terms of Prostate Size Reduction in Prostate Cancer Patients of Intermediate-to-high Risk, Who Require Neoadjuvant Hormone Therapy Prior to Radiotherapy (Curative Intent)
Status: Archived
Summit Research Institute
615
mi
from
Bloomington, IN
Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer
A Randomised, Parallel Arm, Open-label Trial Comparing Degarelix With Goserelin Plus Anti-androgen Flare Protection (Bicalutamide), in Terms of Prostate Size Reduction in Prostate Cancer Patients of Intermediate-to-high Risk, Who Require Neoadjuvant Hormone Therapy Prior to Radiotherapy (Curative Intent)
Status: Archived
Updated: 1/1/1970
Summit Research Institute
615
mi
from
Bloomington, IN
Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer
A Randomised, Parallel Arm, Open-label Trial Comparing Degarelix With Goserelin Plus Anti-androgen Flare Protection (Bicalutamide), in Terms of Prostate Size Reduction in Prostate Cancer Patients of Intermediate-to-high Risk, Who Require Neoadjuvant Hormone Therapy Prior to Radiotherapy (Curative Intent)
Status: Archived
Northeast Indiana Research
716
mi
from
Fort Wayne, IN
Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer
A Randomised, Parallel Arm, Open-label Trial Comparing Degarelix With Goserelin Plus Anti-androgen Flare Protection (Bicalutamide), in Terms of Prostate Size Reduction in Prostate Cancer Patients of Intermediate-to-high Risk, Who Require Neoadjuvant Hormone Therapy Prior to Radiotherapy (Curative Intent)
Status: Archived
Updated: 1/1/1970
Northeast Indiana Research
716
mi
from
Fort Wayne, IN
Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer
A Randomised, Parallel Arm, Open-label Trial Comparing Degarelix With Goserelin Plus Anti-androgen Flare Protection (Bicalutamide), in Terms of Prostate Size Reduction in Prostate Cancer Patients of Intermediate-to-high Risk, Who Require Neoadjuvant Hormone Therapy Prior to Radiotherapy (Curative Intent)
Status: Archived
Urology Center Research Institute
1288
mi
from
Englewood, NJ
Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer
A Randomised, Parallel Arm, Open-label Trial Comparing Degarelix With Goserelin Plus Anti-androgen Flare Protection (Bicalutamide), in Terms of Prostate Size Reduction in Prostate Cancer Patients of Intermediate-to-high Risk, Who Require Neoadjuvant Hormone Therapy Prior to Radiotherapy (Curative Intent)
Status: Archived
Updated: 1/1/1970
Urology Center Research Institute
1288
mi
from
Englewood, NJ
Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer
A Randomised, Parallel Arm, Open-label Trial Comparing Degarelix With Goserelin Plus Anti-androgen Flare Protection (Bicalutamide), in Terms of Prostate Size Reduction in Prostate Cancer Patients of Intermediate-to-high Risk, Who Require Neoadjuvant Hormone Therapy Prior to Radiotherapy (Curative Intent)
Status: Archived
Urology Group of New Mexico
517
mi
from
Albuquerque, NM
Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer
A Randomised, Parallel Arm, Open-label Trial Comparing Degarelix With Goserelin Plus Anti-androgen Flare Protection (Bicalutamide), in Terms of Prostate Size Reduction in Prostate Cancer Patients of Intermediate-to-high Risk, Who Require Neoadjuvant Hormone Therapy Prior to Radiotherapy (Curative Intent)
Status: Archived
Updated: 1/1/1970
Urology Group of New Mexico
517
mi
from
Albuquerque, NM
Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer
A Randomised, Parallel Arm, Open-label Trial Comparing Degarelix With Goserelin Plus Anti-androgen Flare Protection (Bicalutamide), in Terms of Prostate Size Reduction in Prostate Cancer Patients of Intermediate-to-high Risk, Who Require Neoadjuvant Hormone Therapy Prior to Radiotherapy (Curative Intent)
Status: Archived
Premier Medical Group of Hudson
1294
mi
from
Columbia, NY
Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer
A Randomised, Parallel Arm, Open-label Trial Comparing Degarelix With Goserelin Plus Anti-androgen Flare Protection (Bicalutamide), in Terms of Prostate Size Reduction in Prostate Cancer Patients of Intermediate-to-high Risk, Who Require Neoadjuvant Hormone Therapy Prior to Radiotherapy (Curative Intent)
Status: Archived
Updated: 1/1/1970
Premier Medical Group of Hudson
1294
mi
from
Columbia, NY
Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer
A Randomised, Parallel Arm, Open-label Trial Comparing Degarelix With Goserelin Plus Anti-androgen Flare Protection (Bicalutamide), in Terms of Prostate Size Reduction in Prostate Cancer Patients of Intermediate-to-high Risk, Who Require Neoadjuvant Hormone Therapy Prior to Radiotherapy (Curative Intent)
Status: Archived
University Urology Associates
1288
mi
from
, NY
Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer
A Randomised, Parallel Arm, Open-label Trial Comparing Degarelix With Goserelin Plus Anti-androgen Flare Protection (Bicalutamide), in Terms of Prostate Size Reduction in Prostate Cancer Patients of Intermediate-to-high Risk, Who Require Neoadjuvant Hormone Therapy Prior to Radiotherapy (Curative Intent)
Status: Archived
Updated: 1/1/1970
University Urology Associates
1288
mi
from
, NY
Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer
A Randomised, Parallel Arm, Open-label Trial Comparing Degarelix With Goserelin Plus Anti-androgen Flare Protection (Bicalutamide), in Terms of Prostate Size Reduction in Prostate Cancer Patients of Intermediate-to-high Risk, Who Require Neoadjuvant Hormone Therapy Prior to Radiotherapy (Curative Intent)
Status: Archived
Urology Associates
615
mi
from
Nashville, TN
Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer
A Randomised, Parallel Arm, Open-label Trial Comparing Degarelix With Goserelin Plus Anti-androgen Flare Protection (Bicalutamide), in Terms of Prostate Size Reduction in Prostate Cancer Patients of Intermediate-to-high Risk, Who Require Neoadjuvant Hormone Therapy Prior to Radiotherapy (Curative Intent)
Status: Archived
Updated: 1/1/1970
Urology Associates
615
mi
from
Nashville, TN
Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer
A Randomised, Parallel Arm, Open-label Trial Comparing Degarelix With Goserelin Plus Anti-androgen Flare Protection (Bicalutamide), in Terms of Prostate Size Reduction in Prostate Cancer Patients of Intermediate-to-high Risk, Who Require Neoadjuvant Hormone Therapy Prior to Radiotherapy (Curative Intent)
Status: Archived
Urology of Virginia
1186
mi
from
Norfolk, VA
Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer
A Randomised, Parallel Arm, Open-label Trial Comparing Degarelix With Goserelin Plus Anti-androgen Flare Protection (Bicalutamide), in Terms of Prostate Size Reduction in Prostate Cancer Patients of Intermediate-to-high Risk, Who Require Neoadjuvant Hormone Therapy Prior to Radiotherapy (Curative Intent)
Status: Archived
Updated: 1/1/1970
Urology of Virginia
1186
mi
from
Norfolk, VA
Impact of Temsirolimus Therapy on Circulating Tumor Cell Biology In Men With Castration Resistant Metastatic Prostate Cancer
Impact of Temsirolimus Therapy on Circulating Tumor Cell Biology In Men With Castration Resistant Metastatic Prostate Cancer
Status: Archived
Duke Univ Med Ctr
1052
mi
from
Durham, NC
Impact of Temsirolimus Therapy on Circulating Tumor Cell Biology In Men With Castration Resistant Metastatic Prostate Cancer
Impact of Temsirolimus Therapy on Circulating Tumor Cell Biology In Men With Castration Resistant Metastatic Prostate Cancer
Status: Archived
Updated: 1/1/1970
Duke Univ Med Ctr
1052
mi
from
Durham, NC
Impact of Temsirolimus Therapy on Circulating Tumor Cell Biology In Men With Castration Resistant Metastatic Prostate Cancer
Impact of Temsirolimus Therapy on Circulating Tumor Cell Biology In Men With Castration Resistant Metastatic Prostate Cancer
Status: Archived
Virginia Oncology Assoc.
1186
mi
from
Norfolk, VA
Impact of Temsirolimus Therapy on Circulating Tumor Cell Biology In Men With Castration Resistant Metastatic Prostate Cancer
Impact of Temsirolimus Therapy on Circulating Tumor Cell Biology In Men With Castration Resistant Metastatic Prostate Cancer
Status: Archived
Updated: 1/1/1970
Virginia Oncology Assoc.
1186
mi
from
Norfolk, VA
Vitamin E Supplements in Preventing Cancer in Patients at Risk of Prostate Cancer or Who Have Prostate Cancer
A Randomized Study to Investigate the Presence of Tocopherol Metabolites in the Prostate
Status: Archived
University of Medicine and Dentistry - Robert Wood Johnson University Hospital
1263
mi
from
New Brunswick, NJ
Vitamin E Supplements in Preventing Cancer in Patients at Risk of Prostate Cancer or Who Have Prostate Cancer
A Randomized Study to Investigate the Presence of Tocopherol Metabolites in the Prostate
Status: Archived
Updated: 1/1/1970
University of Medicine and Dentistry - Robert Wood Johnson University Hospital
1263
mi
from
New Brunswick, NJ
GE-148-002: A Phase 2, Open-label, Single-Center Study to Assess GE-148 (18F) Injection PET Imaging to Detect Localized Prostate Cancer
GE148-002: A Phase 2, Open-label, Single-Center, Study to Assess GE-148 (18F) Injection Positron Emission Tomography(PET) Imaging to Detect Localized Prostate Cancer
Status: Archived
National Institutes of Health Clinical Center
1123
mi
from
Bethesda, MD
GE-148-002: A Phase 2, Open-label, Single-Center Study to Assess GE-148 (18F) Injection PET Imaging to Detect Localized Prostate Cancer
GE148-002: A Phase 2, Open-label, Single-Center, Study to Assess GE-148 (18F) Injection Positron Emission Tomography(PET) Imaging to Detect Localized Prostate Cancer
Status: Archived
Updated: 1/1/1970
National Institutes of Health Clinical Center
1123
mi
from
Bethesda, MD
A Trial Of Short Term Androgen Deprivation With Pelvic Lymph Node Or Prostate Bed Only Radiotherapy (SPPORT) In Prostate Cancer Patients With A Rising PSA After Radical Prostatectomy
A PHASE III TRIAL OF SHORT TERM ANDROGEN DEPRIVATION WITH PELVIC LYMPH NODE OR PROSTATE BED ONLY RADIOTHERAPY (SPPORT) IN PROSTATE CANCER PATIENTS WITH A RISING PSA AFTER RADICAL PROSTATECTOMY
Status: Archived
Sentara Norfolk General Hospital
1181
mi
from
Norfolk, VA
A Trial Of Short Term Androgen Deprivation With Pelvic Lymph Node Or Prostate Bed Only Radiotherapy (SPPORT) In Prostate Cancer Patients With A Rising PSA After Radical Prostatectomy
A PHASE III TRIAL OF SHORT TERM ANDROGEN DEPRIVATION WITH PELVIC LYMPH NODE OR PROSTATE BED ONLY RADIOTHERAPY (SPPORT) IN PROSTATE CANCER PATIENTS WITH A RISING PSA AFTER RADICAL PROSTATECTOMY
Status: Archived
Updated: 1/1/1970
Sentara Norfolk General Hospital
1181
mi
from
Norfolk, VA
Blood for Immune Response to Provenge® in HRPC
Blood Samples to Evaluate Immune Response to Provenge® (Sipuleucel-T) inHormone Refractory Metastatic Prostate Cancer Patients
Status: Archived
Mary Crowley Cancer Research Center
347
mi
from
Dallas, TX
Blood for Immune Response to Provenge® in HRPC
Blood Samples to Evaluate Immune Response to Provenge® (Sipuleucel-T) inHormone Refractory Metastatic Prostate Cancer Patients
Status: Archived
Updated: 1/1/1970
Mary Crowley Cancer Research Center
347
mi
from
Dallas, TX
Vaccine Therapy in Treating Patients With Progressive Stage D0 Prostate Cancer
A Pilot Study of Vaccination With Epitope-Enhanced TARP Peptide and TARP Peptide-Pulsed Dendritic Cells in the Treatment of Stage D0 Prostate Cancer
Status: Archived
National Cancer Institute (NCI)
1123
mi
from
Bethesda, MD
Vaccine Therapy in Treating Patients With Progressive Stage D0 Prostate Cancer
A Pilot Study of Vaccination With Epitope-Enhanced TARP Peptide and TARP Peptide-Pulsed Dendritic Cells in the Treatment of Stage D0 Prostate Cancer
Status: Archived
Updated: 1/1/1970
National Cancer Institute (NCI)
1123
mi
from
Bethesda, MD
FACBC Positron Emission Tomography/Computed Tomography(PET/CT) Used in the Diagnosis of Primary Prostate Cancer
Anti-[18F]FACBCPET_CT for the Characterization of Primary Prostate Cancer
Status: Archived
Emory Umiversity School of Medicine
803
mi
from
Atlanta, GA
FACBC Positron Emission Tomography/Computed Tomography(PET/CT) Used in the Diagnosis of Primary Prostate Cancer
Anti-[18F]FACBCPET_CT for the Characterization of Primary Prostate Cancer
Status: Archived
Updated: 1/1/1970
Emory Umiversity School of Medicine
803
mi
from
Atlanta, GA
Genomic Guided Therapy With Dasatinib or Nilutamide in Metastatic Castration-Resistant Prostate Cancer
A Phase II Trial of Genomic Guided Therapy With Dasatinib or Nilutamide in Metastatic Castration-Resistant Prostate Cancer
Status: Archived
Duke Univ Med Ctr
1052
mi
from
Durham, NC
Genomic Guided Therapy With Dasatinib or Nilutamide in Metastatic Castration-Resistant Prostate Cancer
A Phase II Trial of Genomic Guided Therapy With Dasatinib or Nilutamide in Metastatic Castration-Resistant Prostate Cancer
Status: Archived
Updated: 1/1/1970
Duke Univ Med Ctr
1052
mi
from
Durham, NC
Genomic Guided Therapy With Dasatinib or Nilutamide in Metastatic Castration-Resistant Prostate Cancer
A Phase II Trial of Genomic Guided Therapy With Dasatinib or Nilutamide in Metastatic Castration-Resistant Prostate Cancer
Status: Archived
Oregon Health and Science University
1383
mi
from
Portland, OR
Genomic Guided Therapy With Dasatinib or Nilutamide in Metastatic Castration-Resistant Prostate Cancer
A Phase II Trial of Genomic Guided Therapy With Dasatinib or Nilutamide in Metastatic Castration-Resistant Prostate Cancer
Status: Archived
Updated: 1/1/1970
Oregon Health and Science University
1383
mi
from
Portland, OR
Genomic Guided Therapy With Dasatinib or Nilutamide in Metastatic Castration-Resistant Prostate Cancer
A Phase II Trial of Genomic Guided Therapy With Dasatinib or Nilutamide in Metastatic Castration-Resistant Prostate Cancer
Status: Archived
University of Washington; UW Medical Center
1382
mi
from
Seattle, WA
Genomic Guided Therapy With Dasatinib or Nilutamide in Metastatic Castration-Resistant Prostate Cancer
A Phase II Trial of Genomic Guided Therapy With Dasatinib or Nilutamide in Metastatic Castration-Resistant Prostate Cancer
Status: Archived
Updated: 1/1/1970
University of Washington; UW Medical Center
1382
mi
from
Seattle, WA
Neoadjuvant Abiraterone Acetate Plus Leuprolide Acetate in Men With Localized High Risk Prostate Cancer
A Phase 2 Open-Label, Randomized, Multi-center Study of Neoadjuvant Abiraterone Acetate (CB7630) Plus Leuprolide Acetate and Prednisone Versus Leuprolide Acetate Alone in Men With Localized High Risk Prostate Cancer
Status: Archived
Dana-Farber Cancer Institute
1444
mi
from
Boston, MA
Neoadjuvant Abiraterone Acetate Plus Leuprolide Acetate in Men With Localized High Risk Prostate Cancer
A Phase 2 Open-Label, Randomized, Multi-center Study of Neoadjuvant Abiraterone Acetate (CB7630) Plus Leuprolide Acetate and Prednisone Versus Leuprolide Acetate Alone in Men With Localized High Risk Prostate Cancer
Status: Archived
Updated: 1/1/1970
Dana-Farber Cancer Institute
1444
mi
from
Boston, MA
Neoadjuvant Abiraterone Acetate Plus Leuprolide Acetate in Men With Localized High Risk Prostate Cancer
A Phase 2 Open-Label, Randomized, Multi-center Study of Neoadjuvant Abiraterone Acetate (CB7630) Plus Leuprolide Acetate and Prednisone Versus Leuprolide Acetate Alone in Men With Localized High Risk Prostate Cancer
Status: Archived
Beth Israel Deaconess Medical Center
1444
mi
from
Boston, MA
Neoadjuvant Abiraterone Acetate Plus Leuprolide Acetate in Men With Localized High Risk Prostate Cancer
A Phase 2 Open-Label, Randomized, Multi-center Study of Neoadjuvant Abiraterone Acetate (CB7630) Plus Leuprolide Acetate and Prednisone Versus Leuprolide Acetate Alone in Men With Localized High Risk Prostate Cancer
Status: Archived
Updated: 1/1/1970
Beth Israel Deaconess Medical Center
1444
mi
from
Boston, MA
Neoadjuvant Abiraterone Acetate Plus Leuprolide Acetate in Men With Localized High Risk Prostate Cancer
A Phase 2 Open-Label, Randomized, Multi-center Study of Neoadjuvant Abiraterone Acetate (CB7630) Plus Leuprolide Acetate and Prednisone Versus Leuprolide Acetate Alone in Men With Localized High Risk Prostate Cancer
Status: Archived
Roswell Park Cancer Center Institute
1054
mi
from
Buffalo, NY
Neoadjuvant Abiraterone Acetate Plus Leuprolide Acetate in Men With Localized High Risk Prostate Cancer
A Phase 2 Open-Label, Randomized, Multi-center Study of Neoadjuvant Abiraterone Acetate (CB7630) Plus Leuprolide Acetate and Prednisone Versus Leuprolide Acetate Alone in Men With Localized High Risk Prostate Cancer
Status: Archived
Updated: 1/1/1970
Roswell Park Cancer Center Institute
1054
mi
from
Buffalo, NY
Neoadjuvant Abiraterone Acetate Plus Leuprolide Acetate in Men With Localized High Risk Prostate Cancer
A Phase 2 Open-Label, Randomized, Multi-center Study of Neoadjuvant Abiraterone Acetate (CB7630) Plus Leuprolide Acetate and Prednisone Versus Leuprolide Acetate Alone in Men With Localized High Risk Prostate Cancer
Status: Archived
University of Texas M.D. Anderson Cancer Center
572
mi
from
Houston, TX
Neoadjuvant Abiraterone Acetate Plus Leuprolide Acetate in Men With Localized High Risk Prostate Cancer
A Phase 2 Open-Label, Randomized, Multi-center Study of Neoadjuvant Abiraterone Acetate (CB7630) Plus Leuprolide Acetate and Prednisone Versus Leuprolide Acetate Alone in Men With Localized High Risk Prostate Cancer
Status: Archived
Updated: 1/1/1970
University of Texas M.D. Anderson Cancer Center
572
mi
from
Houston, TX
Neoadjuvant Abiraterone Acetate Plus Leuprolide Acetate in Men With Localized High Risk Prostate Cancer
A Phase 2 Open-Label, Randomized, Multi-center Study of Neoadjuvant Abiraterone Acetate (CB7630) Plus Leuprolide Acetate and Prednisone Versus Leuprolide Acetate Alone in Men With Localized High Risk Prostate Cancer
Status: Archived
University of Washington
1382
mi
from
Seattle, WA
Neoadjuvant Abiraterone Acetate Plus Leuprolide Acetate in Men With Localized High Risk Prostate Cancer
A Phase 2 Open-Label, Randomized, Multi-center Study of Neoadjuvant Abiraterone Acetate (CB7630) Plus Leuprolide Acetate and Prednisone Versus Leuprolide Acetate Alone in Men With Localized High Risk Prostate Cancer
Status: Archived
Updated: 1/1/1970
University of Washington
1382
mi
from
Seattle, WA
Neoadjuvant Abiraterone Acetate Plus Leuprolide Acetate in Men With Localized High Risk Prostate Cancer
A Phase 2 Open-Label, Randomized, Multi-center Study of Neoadjuvant Abiraterone Acetate (CB7630) Plus Leuprolide Acetate and Prednisone Versus Leuprolide Acetate Alone in Men With Localized High Risk Prostate Cancer
Status: Archived
Wenatchee Valley Medical Center
1318
mi
from
Wenatchee, WA
Neoadjuvant Abiraterone Acetate Plus Leuprolide Acetate in Men With Localized High Risk Prostate Cancer
A Phase 2 Open-Label, Randomized, Multi-center Study of Neoadjuvant Abiraterone Acetate (CB7630) Plus Leuprolide Acetate and Prednisone Versus Leuprolide Acetate Alone in Men With Localized High Risk Prostate Cancer
Status: Archived
Updated: 1/1/1970
Wenatchee Valley Medical Center
1318
mi
from
Wenatchee, WA
A Study of Degarelix in Patients With Prostate Cancer
A Randomized, Controlled, Open-Label Study Investigating the Safety and Efficacy of Degarelix Given Intermittently vs Continuous Androgen Deprivation Therapy With Lupron or Degarelix in Patients With Prostate Cancer With Prior Treatment Failure After Localized Treatment
Status: Archived
Alabama Clinical Research, Inc
746
mi
from
Alexander City, AL
A Study of Degarelix in Patients With Prostate Cancer
A Randomized, Controlled, Open-Label Study Investigating the Safety and Efficacy of Degarelix Given Intermittently vs Continuous Androgen Deprivation Therapy With Lupron or Degarelix in Patients With Prostate Cancer With Prior Treatment Failure After Localized Treatment
Status: Archived
Updated: 1/1/1970
Alabama Clinical Research, Inc
746
mi
from
Alexander City, AL
A Study of Degarelix in Patients With Prostate Cancer
A Randomized, Controlled, Open-Label Study Investigating the Safety and Efficacy of Degarelix Given Intermittently vs Continuous Androgen Deprivation Therapy With Lupron or Degarelix in Patients With Prostate Cancer With Prior Treatment Failure After Localized Treatment
Status: Archived
Urology Center of Alabama, PC
685
mi
from
Homewood, AL
A Study of Degarelix in Patients With Prostate Cancer
A Randomized, Controlled, Open-Label Study Investigating the Safety and Efficacy of Degarelix Given Intermittently vs Continuous Androgen Deprivation Therapy With Lupron or Degarelix in Patients With Prostate Cancer With Prior Treatment Failure After Localized Treatment
Status: Archived
Updated: 1/1/1970
Urology Center of Alabama, PC
685
mi
from
Homewood, AL
A Study of Degarelix in Patients With Prostate Cancer
A Randomized, Controlled, Open-Label Study Investigating the Safety and Efficacy of Degarelix Given Intermittently vs Continuous Androgen Deprivation Therapy With Lupron or Degarelix in Patients With Prostate Cancer With Prior Treatment Failure After Localized Treatment
Status: Archived
Advanced Urology Medical Center
1155
mi
from
Anaheim, CA
A Study of Degarelix in Patients With Prostate Cancer
A Randomized, Controlled, Open-Label Study Investigating the Safety and Efficacy of Degarelix Given Intermittently vs Continuous Androgen Deprivation Therapy With Lupron or Degarelix in Patients With Prostate Cancer With Prior Treatment Failure After Localized Treatment
Status: Archived
Updated: 1/1/1970
Advanced Urology Medical Center
1155
mi
from
Anaheim, CA
A Study of Degarelix in Patients With Prostate Cancer
A Randomized, Controlled, Open-Label Study Investigating the Safety and Efficacy of Degarelix Given Intermittently vs Continuous Androgen Deprivation Therapy With Lupron or Degarelix in Patients With Prostate Cancer With Prior Treatment Failure After Localized Treatment
Status: Archived
Peninsula Urology Medical Center
1330
mi
from
Atherton, CA
A Study of Degarelix in Patients With Prostate Cancer
A Randomized, Controlled, Open-Label Study Investigating the Safety and Efficacy of Degarelix Given Intermittently vs Continuous Androgen Deprivation Therapy With Lupron or Degarelix in Patients With Prostate Cancer With Prior Treatment Failure After Localized Treatment
Status: Archived
Updated: 1/1/1970
Peninsula Urology Medical Center
1330
mi
from
Atherton, CA
A Study of Degarelix in Patients With Prostate Cancer
A Randomized, Controlled, Open-Label Study Investigating the Safety and Efficacy of Degarelix Given Intermittently vs Continuous Androgen Deprivation Therapy With Lupron or Degarelix in Patients With Prostate Cancer With Prior Treatment Failure After Localized Treatment
Status: Archived
Urology Associates of Central CA
1204
mi
from
Fresno, CA
A Study of Degarelix in Patients With Prostate Cancer
A Randomized, Controlled, Open-Label Study Investigating the Safety and Efficacy of Degarelix Given Intermittently vs Continuous Androgen Deprivation Therapy With Lupron or Degarelix in Patients With Prostate Cancer With Prior Treatment Failure After Localized Treatment
Status: Archived
Updated: 1/1/1970
Urology Associates of Central CA
1204
mi
from
Fresno, CA
A Study of Degarelix in Patients With Prostate Cancer
A Randomized, Controlled, Open-Label Study Investigating the Safety and Efficacy of Degarelix Given Intermittently vs Continuous Androgen Deprivation Therapy With Lupron or Degarelix in Patients With Prostate Cancer With Prior Treatment Failure After Localized Treatment
Status: Archived
South Orange County Medical Research
1150
mi
from
Laguna Hills, CA
A Study of Degarelix in Patients With Prostate Cancer
A Randomized, Controlled, Open-Label Study Investigating the Safety and Efficacy of Degarelix Given Intermittently vs Continuous Androgen Deprivation Therapy With Lupron or Degarelix in Patients With Prostate Cancer With Prior Treatment Failure After Localized Treatment
Status: Archived
Updated: 1/1/1970
South Orange County Medical Research
1150
mi
from
Laguna Hills, CA
A Study of Degarelix in Patients With Prostate Cancer
A Randomized, Controlled, Open-Label Study Investigating the Safety and Efficacy of Degarelix Given Intermittently vs Continuous Androgen Deprivation Therapy With Lupron or Degarelix in Patients With Prostate Cancer With Prior Treatment Failure After Localized Treatment
Status: Archived
Atlantic Urology Medical Group
1172
mi
from
Long Beach, CA
A Study of Degarelix in Patients With Prostate Cancer
A Randomized, Controlled, Open-Label Study Investigating the Safety and Efficacy of Degarelix Given Intermittently vs Continuous Androgen Deprivation Therapy With Lupron or Degarelix in Patients With Prostate Cancer With Prior Treatment Failure After Localized Treatment
Status: Archived
Updated: 1/1/1970
Atlantic Urology Medical Group
1172
mi
from
Long Beach, CA
A Study of Degarelix in Patients With Prostate Cancer
A Randomized, Controlled, Open-Label Study Investigating the Safety and Efficacy of Degarelix Given Intermittently vs Continuous Androgen Deprivation Therapy With Lupron or Degarelix in Patients With Prostate Cancer With Prior Treatment Failure After Localized Treatment
Status: Archived
Tower Urology Medical Group
1168
mi
from
Los Angeles, CA
A Study of Degarelix in Patients With Prostate Cancer
A Randomized, Controlled, Open-Label Study Investigating the Safety and Efficacy of Degarelix Given Intermittently vs Continuous Androgen Deprivation Therapy With Lupron or Degarelix in Patients With Prostate Cancer With Prior Treatment Failure After Localized Treatment
Status: Archived
Updated: 1/1/1970
Tower Urology Medical Group
1168
mi
from
Los Angeles, CA
A Study of Degarelix in Patients With Prostate Cancer
A Randomized, Controlled, Open-Label Study Investigating the Safety and Efficacy of Degarelix Given Intermittently vs Continuous Androgen Deprivation Therapy With Lupron or Degarelix in Patients With Prostate Cancer With Prior Treatment Failure After Localized Treatment
Status: Archived
San Bernandino Urology
1113
mi
from
San Bernardino, CA
A Study of Degarelix in Patients With Prostate Cancer
A Randomized, Controlled, Open-Label Study Investigating the Safety and Efficacy of Degarelix Given Intermittently vs Continuous Androgen Deprivation Therapy With Lupron or Degarelix in Patients With Prostate Cancer With Prior Treatment Failure After Localized Treatment
Status: Archived
Updated: 1/1/1970
San Bernandino Urology
1113
mi
from
San Bernardino, CA
A Study of Degarelix in Patients With Prostate Cancer
A Randomized, Controlled, Open-Label Study Investigating the Safety and Efficacy of Degarelix Given Intermittently vs Continuous Androgen Deprivation Therapy With Lupron or Degarelix in Patients With Prostate Cancer With Prior Treatment Failure After Localized Treatment
Status: Archived
Urological Physicians of S.D.
1143
mi
from
San Diego, CA
A Study of Degarelix in Patients With Prostate Cancer
A Randomized, Controlled, Open-Label Study Investigating the Safety and Efficacy of Degarelix Given Intermittently vs Continuous Androgen Deprivation Therapy With Lupron or Degarelix in Patients With Prostate Cancer With Prior Treatment Failure After Localized Treatment
Status: Archived
Updated: 1/1/1970
Urological Physicians of S.D.
1143
mi
from
San Diego, CA
A Study of Degarelix in Patients With Prostate Cancer
A Randomized, Controlled, Open-Label Study Investigating the Safety and Efficacy of Degarelix Given Intermittently vs Continuous Androgen Deprivation Therapy With Lupron or Degarelix in Patients With Prostate Cancer With Prior Treatment Failure After Localized Treatment
Status: Archived
San Diego Uro-Research
1143
mi
from
San Diego, CA
A Study of Degarelix in Patients With Prostate Cancer
A Randomized, Controlled, Open-Label Study Investigating the Safety and Efficacy of Degarelix Given Intermittently vs Continuous Androgen Deprivation Therapy With Lupron or Degarelix in Patients With Prostate Cancer With Prior Treatment Failure After Localized Treatment
Status: Archived
Updated: 1/1/1970
San Diego Uro-Research
1143
mi
from
San Diego, CA